| Indicators | Browse All

Dermata Therapeutics, Inc. (DRMA)

Healthcare | Biotechnology | San Diego, United States | NasdaqCM
1.34 USD -0.01 (-1.111%) ⇩ (July 14, 2026, 9:41 a.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:13 a.m. EDT

The immediate outlook remains heavily skewed toward caution due to a catastrophic multi-year price collapse. Over the last three years, the stock has lost nearly 99.6% of its value, with every single year showing a double-digit percentage decline. This relentless downward trajectory suggests the market has thoroughly rejected the company's current business model and execution, regardless of recent executive appointments or minor capital raises. While the recent price action shows a slight bounce off the lows, the sheer magnitude of the prior destruction makes any short-term recovery highly speculative rather than a high-conviction setup. From a fundamental perspective, the investment case is severely compromised. The company is burning through cash rapidly, evidenced by significant negative operating and free cash flows, while posting substantial losses in both assets and equity. The balance sheet, though currently bolstered by a high current ratio, is propped up by a massive cash pile relative to its tiny market cap—a classic sign of a distressed biotech firm raising money just to survive. With no analyst coverage, a negative forward P/E, and a lack of profitability, there is no safety margin here; the stock is trading at a discount because the future prospects appear bleak. Finally, income investors will find nothing of interest. There is no dividend history and no payout mechanism in place. For a company in this precarious financial state, any distribution would likely be unsustainable and detrimental to operations. In summary, this is a high-risk speculative vehicle where the odds favor further downside or a binary event-driven recovery, making it unsuitable for standard investment strategies.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.039553
AutoETS0.040256
AutoTheta0.041154
AutoARIMA0.041335

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 38%
H-stat 1.24
Ljung-Box p 0.000
Jarque-Bera p 0.343
Excess Kurtosis -0.90
Attribute Value
Sector Healthcare
Market Cap 5,369,561
Forward P/E -0.34
Beta 0.67
Website https://www.dermatarx.com

Info Dump

Attribute Value
52 Week Change -0.8150685
Address1 3,525 Del Mar Heights Rd.
Address2 Suite 332
All Time High 16,680.0
All Time Low 1.1
Ask 1.7
Ask Size 2
Average Daily Volume10 Day 112,660
Average Daily Volume3 Month 73,914
Average Volume 73,914
Average Volume10Days 112,660
Beta 0.667
Bid 0.9432
Bid Size 2
Book Value 1.594
City San Diego
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.335
Current Ratio 7.092
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 1.34
Day Low 1.335
Display Name Dermata Therapeutics
Earnings Timestamp End 1,747,225,800
Earnings Timestamp Start 1,747,225,800
Ebitda Margins 0.0
Enterprise Value -1,515,389
Eps Forward -3.87
Eps Trailing Twelve Months -4.26
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.2684
Fifty Day Average Change 0.066600084
Fifty Day Average Change Percent 0.052507162
Fifty Two Week Change Percent -81.50685
Fifty Two Week High 7.78
Fifty Two Week High Change -6.445
Fifty Two Week High Change Percent -0.82840616
Fifty Two Week Low 1.1
Fifty Two Week Low Change 0.23500001
Fifty Two Week Low Change Percent 0.21363637
Fifty Two Week Range 1.1 - 7.78
Financial Currency USD
First Trade Date Milliseconds 1,628,861,400,000
Float Shares 3,169,006
Forward Eps -3.87
Forward P E -0.34496126
Free Cashflow -6,336,057
Full Exchange Name NasdaqCM
Full Time Employees 9
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.24816999
Held Percent Institutions 0.07374
Implied Shares Outstanding 4,022,143
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-08-13
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,754,006,400
Last Split Factor 1:10
Long Business Summary Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Long Name Dermata Therapeutics, Inc.
Market us_market
Market Cap 5,369,561
Market State REGULAR
Max Age 86,400
Message Board Id finmb_283634456
Most Recent Quarter 1,774,915,200
Net Income To Common -7,102,676
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 5,429,893
Number Of Analyst Opinions 1
Open 1.34
Operating Cashflow -8,303,211
Operating Margins 0.0
Payout Ratio 0.0
Phone 858 800 2543
Previous Close 1.35
Price Hint 4
Price To Book 0.8375157
Profit Margins 0.0
Quick Ratio 6.598
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.014999986
Regular Market Change Percent -1.1111101
Regular Market Day High 1.34
Regular Market Day Low 1.335
Regular Market Day Range 1.335 - 1.34
Regular Market Open 1.34
Regular Market Previous Close 1.35
Regular Market Price 1.335
Regular Market Time 1,784,036,507
Regular Market Volume 2,381
Return On Assets -0.52661
Return On Equity -1.03581
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 4,022,143
Shares Percent Shares Out 0.0327
Shares Short 131,494
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 96,498
Short Name Dermata Therapeutics, Inc.
Short Percent Of Float 0.0417
Short Ratio 1.59
Source Interval 15
State CA
Symbol DRMA
Target High Price 4.0
Target Low Price 4.0
Target Mean Price 4.0
Target Median Price 4.0
Total Cash 6,945,282
Total Cash Per Share 1.727
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.26
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.128725
Two Hundred Day Average Change -0.793725
Two Hundred Day Average Change Percent -0.37286404
Type Disp Equity
Volume 2,381
Website https://www.dermatarx.com
Zip 92,130